Outcome for pediatric acute promyelocytic leukemia patients at Children’s Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance)

Kutny MA, Geyer S, Laumann KM, Gregory J, Willman CL, Stock W, Larson RA, Powell BL, Feusner JH. Outcome for pediatric acute promyelocytic leukemia patients at Children’s Oncology Group sites on the Leukemia Intergroup Study CALGB 9710 (Alliance). Pediatr Blood Cancer. 2019 Mar;66(3):e27542. doi: 10.1002/pbc.27542. Epub 2018 Nov 4. PMID: 30393935; PMCID: PMC6392047.

Acute promyelocytic leukemia (APL) is a unique leukemia subtype requiring specialized treatment including all-trans retinoic acid (ATRA). A prior report demonstrated worse outcome among young children <5 years old compared to older children. We evaluated outcomes for pediatric patients (<18 years old; N=83) with APL treated on North American Intergroup study CALGB 9710 at Children’s Oncology Group sites. Induction and consolidation included ATRA, cytarabine and anthracyclines. Patients ≥15 years old were randomized to addition of arsenic trioxide (ATO) consolidation. All patients were randomized to ATRA maintenance with vs without oral chemotherapy.